Bristol-Myers Faces Challenges

NEW YORK ( TheStreet) -- The business of being a international pharmaceutical company is challenging and fraught with all kinds of situations.

For every big business, as the old song goes, "sometimes you win and sometimes you lose, and sometimes the blues gets a hold of you..." That song would be appropriate after a Food and Drug Administration rejection or when a drug loses its patent protection and becomes fair game for generic drug manufacturers.

When an investor studies the recent history of Bristol-Myers Squibb ( BMY), one can see something very similar. Back in 2012 BMY lost patent protection on its blockbuster blood-thinning drug Plavix. It was an expensive loss.

To attempt to rebound from this multi-billion-dollar revenue driver, BMY went into high gear and ever since has done its utmost to redefine itself and its product line. The results have been so positive that BMY shares recently hit a 52-week high of $37.60 on Tuesday.

Let's take a peek at a five-year chart that is certain to impress shareholders and potential shareholders alike. I've included the trailing 12-month revenue per share, which peaked almost a year ago.

BMY Chart BMY data by YCharts

It illustrates the challenge BMY faces, unless BMY is taken over by a bigger drug company or if BMY can buy another revenue driver from one of its smaller competitors.

Both possibilities are realistic. BMY, with its current market cap of $61.5 billion, could conceivably be "affordable" for a Jolly Giant like Johnson & Johnson ( JNJ), which also hit a 52-week high Tuesday of $77.71, leaving its market cap somewhere north of a colossal $217 billion.

According to the BMY Web site that speaks about its product development it is working on a new-generation blood-thinner called Eliquis as well as drugs for the growing need to successfully treat widespread health problems such as hepatitis C and cancer.

According to the Web site:
In 2011, we invested $3.8 billion in the discovery and development of medicines in key areas such as diabetes, oncology, cardiovascular, neuroscience, virology and immunology.

The company then lists from A to Z the names of these drugs BMY refers to as its "string of pearls" -- its product pipeline.

Can BMY develop or buy more "pearls" that it can add to its "string?" We might find out soon when the company presents at the Barclays 2013 Global Health Care Conference on Tuesday, March 12, in Miami.

Michael Giordano, senior vice president and head of Development, Oncology & Immunology, will make a formal presentation about the company at 9:30 a.m. ET. It would not surprise me to hear some encouraging news as to the BMY strategy going forward on filling its pipeline and at the very least sustaining the sales profits at the 2012 levels.

By the end of 2012 BMY had operating cash flow of nearly $7 billion and total cash (most recent quarter) of $2.83 billion. It can generate more revenue with wider distribution of Eliquis, which has been touted as a drug that can prevent strokes. It will be sold in partnership with Pfizer ( PFE).

There are numerous other ways BMY can preserve and grow its triumphant share price including international sales expansions in areas like Asia. The challenges the world faces with diseases like hepatitis C are growing, and by some estimates could eventually present a $5 billion to $10 billion market if aggressively marketed.

In the meantime don't count out the possibility that BMY is already on the radar screen of some cashed-up predators that will pay dearly for its "string of pearls" including the ones in late-stage development.

At the time of publication the author had a position in PFE.

This article was written by an independent contributor, separate from TheStreet's regular news coverage.

Make smarter trading decisions and provide investment ideas that could help make you richer. Bryan Ashenberg does the dirty work so you don't have to!

If you liked this article you might like

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Bristol-Myers 'Is Back' and Could Soar Another 14%

Bristol-Myers 'Is Back' and Could Soar Another 14%

These Were the 3 Hottest Stories on Wall Street Thursday

These Were the 3 Hottest Stories on Wall Street Thursday

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

Rock and Roll: Bristol-Myers Squibb Is Breaking Out

Dow Soars Over 250 Points to Post Its Fourth Straight Day of Gains